Lifeboat Foundation

The Silicon Hospital is OpenWater’s revolutionary open-source software and hardware platform.

Drug delivery researchers at Oregon State University have developed a device with the potential to improve gene therapy for patients with inherited lung diseases such as cystic fibrosis.

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed a nanoparticle that can penetrate the blood-brain barrier. Their goal is to kill primary breast cancer tumors and brain metastases in one treatment, and their research shows the method can shrink breast and brain tumors in laboratory studies.

The team, led by Dipanjan Pan, Dorothy Foehr Huck & J. Lloyd Huck Chair Professor in Nanomedicine and professor of materials science and engineering and of nuclear engineering, published their work —the first of its kind, they said—in ACS Nano.

“Borophene is a very interesting material, as it resembles carbon very closely including its atomic weight and electron structure but with more remarkable properties. Researchers are only starting to explore its applications,” Pan said.

“To the best of our knowledge, this is the first study to understand the biological interactions of borophene and the first report of imparting chirality on borophene structures.”

Researchers have developed a new vaccine technology that has been shown in mice to provide protection against a broad range of coronaviruses with potential for future disease outbreaks—including ones we don’t even know about. The results are published in the journal Nature Nanotechnology.

Skin functions as a sophisticated sensorial system in the human body, capable not only of detecting environmental stimuli—such as temperature, pressure, strain, and vibration—but also of actively responding to these changes. Among these, the temperature regulation capability of the skin plays a critical role in maintaining the stability of homeothermic animals.

An international team, led by researchers from Australia, have developed a system using nanotechnology that could allow people with diabetes to take oral insulin in the future. The researchers say the new insulin could be eaten by taking a tablet or even embedded within a piece of chocolate.

A team of chemists and bioengineers at Rice University and the University of Houston have achieved a significant milestone in their work to create a biomaterial that can be used to grow biological tissues outside the human body.

The results of a metagenomic study from the University of Trento suggest that the CRISPR toolbox will need to make room for another CRISPR enzyme. The disruption should be minimal because the newly identified enzyme is unusually compact. It consists of just over 1,000 amino acids. And yet it is also strongly active and highly precise. The hope is that it can be packaged with guide RNA within the tight quarters afforded by adeno-associated virus (AAV) vectors, and thereby expand the use of in vivo gene editing in therapeutic applications.

The study was led by Anna Cereseto, PhD, and Nicola Segata, PhD, of the department of cellular, computational, and integrative biology. Cereseto leads a laboratory that develops advanced genome editing technologies and their application in the medical sector. Segata is the head of a laboratory of metagenomics, where he studies the variety and characteristics of the human microbiome and its role in health. Their collaboration has led to the identification, in a bacterium of the intestine, of new CRISPR-Cas9 molecules that could have a clinical potential to treat genetic diseases.

Detailed findings from the study recently appeared in Nature Communications, in an article titled, “CoCas9 is a compact nuclease from the human microbiome for efficient and precise genome editing.”